21-29043492-G-A
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_006447.3(USP16):c.1249G>A(p.Glu417Lys) variant causes a missense change. The variant allele was found at a frequency of 0.000092 in 1,597,270 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.00018 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000083 ( 0 hom. )
Consequence
USP16
NM_006447.3 missense
NM_006447.3 missense
Scores
1
6
12
Clinical Significance
Conservation
PhyloP100: 6.26
Genes affected
USP16 (HGNC:12614): (ubiquitin specific peptidase 16) This gene encodes a deubiquitinating enzyme that is phosphorylated at the onset of mitosis and then dephosphorylated at the metaphase/anaphase transition. It can deubiquitinate H2A, one of two major ubiquitinated proteins of chromatin, in vitro and a mutant form of the protein was shown to block cell division. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.25965643).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
USP16 | NM_006447.3 | c.1249G>A | p.Glu417Lys | missense_variant | 13/18 | ENST00000399976.7 | NP_006438.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
USP16 | ENST00000399976.7 | c.1249G>A | p.Glu417Lys | missense_variant | 13/18 | 1 | NM_006447.3 | ENSP00000382858 | P5 | |
USP16 | ENST00000399975.7 | c.1246G>A | p.Glu416Lys | missense_variant | 13/18 | 1 | ENSP00000382857 | A1 | ||
USP16 | ENST00000474835.5 | n.2311G>A | non_coding_transcript_exon_variant | 12/17 | 1 | |||||
USP16 | ENST00000334352.8 | c.1249G>A | p.Glu417Lys | missense_variant | 14/19 | 5 | ENSP00000334808 | P5 |
Frequencies
GnomAD3 genomes AF: 0.000178 AC: 27AN: 152054Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
27
AN:
152054
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000837 AC: 20AN: 238858Hom.: 0 AF XY: 0.000124 AC XY: 16AN XY: 129546
GnomAD3 exomes
AF:
AC:
20
AN:
238858
Hom.:
AF XY:
AC XY:
16
AN XY:
129546
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000830 AC: 120AN: 1445096Hom.: 0 Cov.: 30 AF XY: 0.0000946 AC XY: 68AN XY: 718582
GnomAD4 exome
AF:
AC:
120
AN:
1445096
Hom.:
Cov.:
30
AF XY:
AC XY:
68
AN XY:
718582
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000177 AC: 27AN: 152174Hom.: 0 Cov.: 33 AF XY: 0.000175 AC XY: 13AN XY: 74424
GnomAD4 genome
AF:
AC:
27
AN:
152174
Hom.:
Cov.:
33
AF XY:
AC XY:
13
AN XY:
74424
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
3
ExAC
AF:
AC:
16
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 10, 2023 | The c.1249G>A (p.E417K) alteration is located in exon 14 (coding exon 12) of the USP16 gene. This alteration results from a G to A substitution at nucleotide position 1249, causing the glutamic acid (E) at amino acid position 417 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Pathogenic
DEOGEN2
Benign
.;T;T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;.;D
M_CAP
Benign
T
MetaRNN
Benign
T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
.;L;L
MutationTaster
Benign
D;D;D;D
PrimateAI
Uncertain
T
PROVEAN
Benign
N;N;N
REVEL
Benign
Sift
Uncertain
D;D;D
Sift4G
Benign
T;T;T
Polyphen
D;D;D
Vest4
MVP
MPC
0.12
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at